These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

753 related items for PubMed ID: 20886718

  • 21. Immunophenotypic shift in the B-cell precursors from regenerating bone marrow samples: A critical consideration for measurable residual disease assessment in B-lymphoblastic leukemia.
    Chatterjee G, Sriram H, Ghogale S, Deshpande N, Khanka T, Panda D, Pradhan SN, Girase K, Narula G, Dhamane C, Malik NR, Banavali S, Patkar NV, Gujral S, Subramanian PG, Tembhare PR.
    Cytometry B Clin Cytom; 2021 Jul; 100(4):434-445. PubMed ID: 32896101
    [Abstract] [Full Text] [Related]

  • 22. Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000.
    Tembhare PR, Ghogale S, Ghatwai N, Badrinath Y, Kunder N, Patkar NV, Bibi AR, Chatterjee G, Arora B, Narula G, Banawali S, Deshpande N, Amare P, Gujral S, Subramanian PG.
    Cytometry B Clin Cytom; 2018 Jan; 94(1):100-111. PubMed ID: 27718302
    [Abstract] [Full Text] [Related]

  • 23. [Clinical significance for minimal residual disease detection by 4 color flow cytometry in adult and childhood B lineage acute lymphoblastic leukemia].
    Liu YR, Zhang LP, Chang Y, Cheng YF, Fu JY, Li LD, Wang H, Liu GL, Chen SS, Huang XJ, Lu DP.
    Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):302-5. PubMed ID: 16875577
    [Abstract] [Full Text] [Related]

  • 24. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
    Muñoz L, López O, Martino R, Brunet S, Bellido M, Rubiol E, Sierra J, Nomdedéu JF.
    Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
    [Abstract] [Full Text] [Related]

  • 25. Immunophenotypic expression and immunomodulation in minimal residual disease analysis of pediatric B acute lymphoblastic leukemia by high sensitive flow cytometry.
    Arumugam JR, Bommannan K, Radhakrishnan V, Sagar TG, Sundersingh S.
    Leuk Lymphoma; 2022 Mar; 63(3):644-652. PubMed ID: 34727819
    [Abstract] [Full Text] [Related]

  • 26. [Analysis of immunophenotype and leukemia associated immunophenotype in 610 patients with acute myeloid leukemia].
    Liu YR, Wang YZ, Chen SS, Chang Y, Fu JY, Li LD, Wang H, Yu H, Jiang B, Huang XJ.
    Zhonghua Xue Ye Xue Za Zhi; 2007 Nov; 28(11):731-6. PubMed ID: 18457262
    [Abstract] [Full Text] [Related]

  • 27. The immunophenotypes of blast cells in B-cell precursor acute lymphoblastic leukemia: how different are they from their normal counterparts?
    Sędek Ł, Bulsa J, Sonsala A, Twardoch M, Wieczorek M, Malinowska I, Derwich K, Niedźwiecki M, Sobol-Milejska G, Kowalczyk JR, Mazur B, Szczepański T.
    Cytometry B Clin Cytom; 2014 Sep; 86(5):329-39. PubMed ID: 24845957
    [Abstract] [Full Text] [Related]

  • 28. Immunophenotypic aberrancies in acute lymphoblastic leukemia from 282 Iraqi patients.
    Jalal SD, Al-Allawi NAS, Al Doski AAS.
    Int J Lab Hematol; 2017 Dec; 39(6):625-632. PubMed ID: 28722319
    [Abstract] [Full Text] [Related]

  • 29. [Comparison of the immunophenotype of patients with B lineage acute lymphoblastic leukemia at diagnosis and relapse].
    Liu YR, Chang Y, Fu JY, Cheng YF, Zhang LP, Li LD, Wang H, Liu GL, Chen SS, Huang XJ, Lu DP.
    Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):335-8. PubMed ID: 16875586
    [Abstract] [Full Text] [Related]

  • 30. CD19 negative precursor B acute lymphoblastic leukemia (B-ALL)-Immunophenotypic challenges in diagnosis and monitoring: A study of three cases.
    Ghodke K, Bibi A, Rabade N, Patkar N, Subramanian PG, Kadam PA, Badrinath Y, Ghogale S, Gujral S, Tembhare P.
    Cytometry B Clin Cytom; 2017 Jul; 92(4):315-318. PubMed ID: 27018867
    [Abstract] [Full Text] [Related]

  • 31. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
    Ling JY, Sun XF, Yan SL, He LR, Zhen ZJ, Xia Y.
    Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665
    [Abstract] [Full Text] [Related]

  • 32. [The limited possibility of using a simplified approach to detect minimal residual disease by the flow cytometry technique in children with precursor B-lineage acute lymphoblastic leukemia].
    Popov AM, Verzhbitskaia T, Tsaur GA, Shorikov EV, Tsvirenko SV, Savel'ev LI, Fechina LG.
    Klin Lab Diagn; 2011 Mar; (3):25-9. PubMed ID: 21574456
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease.
    Dworzak MN, Fröschl G, Printz D, Zen LD, Gaipa G, Ratei R, Basso G, Biondi A, Ludwig WD, Gadner H.
    Leukemia; 2004 Apr; 18(4):703-8. PubMed ID: 14961034
    [Abstract] [Full Text] [Related]

  • 35. Flow cytometric analysis of de novo acute lymphoblastic leukemia in childhood: report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
    Iwamoto S, Deguchi T, Ohta H, Kiyokawa N, Tsurusawa M, Yamada T, Takase K, Fujimoto J, Hanada R, Hori H, Horibe K, Komada Y.
    Int J Hematol; 2011 Aug; 94(2):185-192. PubMed ID: 21800074
    [Abstract] [Full Text] [Related]

  • 36. Lymphoblastic lymphoma.
    Cortelazzo S, Ponzoni M, Ferreri AJ, Hoelzer D.
    Crit Rev Oncol Hematol; 2011 Sep; 79(3):330-43. PubMed ID: 21273093
    [Abstract] [Full Text] [Related]

  • 37. Implementation of a simplified flow cytometric assays for minimal residual disease monitoring in childhood acute lymphoblastic leukemia.
    Vinhas E, Lucena-Silva N, Pedrosa F.
    Cytometry B Clin Cytom; 2018 Jan; 94(1):94-99. PubMed ID: 27342632
    [Abstract] [Full Text] [Related]

  • 38. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.
    Gaipa G, Basso G, Biondi A, Campana D.
    Cytometry B Clin Cytom; 2013 Jan; 84(6):359-69. PubMed ID: 23757107
    [Abstract] [Full Text] [Related]

  • 39. The significance of peripheral blood minimal residual disease to predict early disease response in patients with B-cell acute lymphoblastic leukemia.
    Setiadi A, Owen D, Tsang A, Milner R, Vercauteren S.
    Int J Lab Hematol; 2016 Oct; 38(5):527-34. PubMed ID: 27339737
    [Abstract] [Full Text] [Related]

  • 40. B-lineage antigens that are useful to substitute CD19 for minimal residual disease monitoring in B cell precursor acute lymphoblastic leukemia after CD19 targeting.
    Mikhailova E, Itov A, Zerkalenkova E, Roumiantseva J, Olshanskaya Y, Karachunskiy A, Novichkova G, Maschan M, Popov A.
    Cytometry B Clin Cytom; 2022 Sep; 102(5):353-359. PubMed ID: 35796438
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 38.